Sonnet BioTherapeutics (SONN) Short Interest Ratio & Short Volume → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free SONN Stock Alerts $1.80 +0.01 (+0.56%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Sonnet BioTherapeutics Short Interest DataCurrent Short Volume400,200 sharesPrevious Short Volume424,200 sharesChange Vs. Previous Month-5.66%Dollar Volume Sold Short$708,354.00Short Interest Ratio / Days to Cover4.0Last Record DateApril 30, 2024Outstanding Shares3,069,000 sharesFloat Size2,780,000 sharesShort Percent of Float14.40%Today's Trading Volume14,577 sharesAverage Trading Volume76,228 sharesToday's Volume Vs. Average19% Short Selling Sonnet BioTherapeutics ? Sign up to receive the latest short interest report for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatSONN Short Interest Over TimeSONN Days to Cover Over TimeSONN Percentage of Float Shorted Over Time Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. Sonnet BioTherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024400,200 shares $708,354.00 -5.7%14.4%4 $1.77 4/15/2024424,200 shares $767,802.00 -6.2%15.3%4.3 $1.81 3/31/2024452,200 shares $841,092.00 -18.9%16.3%4.5 $1.86 3/15/2024557,500 shares $1.13 million +119.4%20.1%5.1 $2.02 2/29/2024254,100 shares $500,577.00 +9.5%9.1%2.5 $1.97 2/15/2024232,100 shares $378,323.00 +38.8%8.4%4.7 $1.63 Get the Latest News and Ratings for SONN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024167,200 shares $244,112.00 +2.0%6.0%3 $1.46 1/15/2024163,900 shares $219,626.00 +44.5%5.9%2.2 $1.34 12/31/2023113,400 shares $197,316.00 +21.2%4.1%1.5 $1.74 12/15/202393,600 shares $131,976.00 +49.5%3.4%1.3 $1.41 11/30/202362,600 shares $87,014.00 +18.1%2.4%0.9 $1.39 11/15/202353,000 shares $68,900.00 -11.5%2.0%0.7 $1.30 10/31/202359,900 shares $74,276.00 +24.5%2.5%0.7 $1.24 10/15/202348,100 shares $111,592.00 -9.3%3.3%0.7 $2.32 9/30/202353,000 shares $151,845.00 +59.6%3.7%0.7 $2.87 9/15/202333,200 shares $119,520.00 -1.2%2.3%0.4 $3.60 8/31/202333,600 shares $147,840.00 -94.1%2.3%0.3 $4.40 8/15/2023570,500 shares $186,610.55 +59.9%N/A0.1 $0.33 7/31/2023356,700 shares $118,638.42 -39.4%N/A0.1 $0.33 7/15/2023588,400 shares $255,306.76 -19.4%N/A0.1 $0.43 6/30/2023729,900 shares $357,651.00 -64.2%N/A0.2 $0.49 6/15/20232,040,000 shares $1.90 million -24.2%13.6%0.5 $0.93 5/31/20232,690,000 shares $1.38 million +441.9%15.7%0.9 $0.51 5/15/2023496,400 shares $111,044.68 -46.1%2.8%0.3 $0.22 4/30/2023921,700 shares $220,747.15 +255.7%5.0%0.9 $0.24 4/15/2023259,100 shares $94,571.50 +115.4%1.3%0.3 $0.37 3/31/2023120,300 shares $43,308.00 -45.2%0.6%0.2 $0.36 3/15/2023219,500 shares $122,963.90 -41.0%1.1%0.4 $0.56 2/28/2023372,200 shares $314,397.34 -30.7%1.9%0.8 $0.84 2/15/2023536,700 shares $520,545.33 +197.5%2.8%1.1 $0.97 1/31/2023180,400 shares $207,460.00 -46.7%2.4%0.2 $1.15 1/15/2023338,700 shares $477,567.00 +154.7%4.5%0.1 $1.41 12/30/2022133,000 shares $152,950.00 +830.1%1.8%0 $1.15 12/15/202214,300 shares $13,871.00 -96.0%0.2%0 $0.97 11/30/2022359,900 shares $359,900.00 +11.7%8.7%0.1 $1.00 11/15/2022322,300 shares $393,206.00 +125.4%7.8%0.1 $1.22 10/31/2022143,000 shares $275,990.00 -15.8%3.5%0 $1.93 10/15/2022169,800 shares $212,250.00 -74.0%4.1%0.5 $1.25 9/30/2022652,200 shares $958,734.00 +1,427.4%15.7%1.9 $1.47 9/15/202242,700 shares $135,700.60 -88.3%1.0%0.1 $3.18[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. SONN Short Interest - Frequently Asked Questions What is Sonnet BioTherapeutics' current short interest? Short interest is the volume of Sonnet BioTherapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 400,200 shares of SONN short. 14.40% of Sonnet BioTherapeutics' shares are currently sold short. Learn More on Sonnet BioTherapeutics' current short interest. What is a good short interest ratio for Sonnet BioTherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SONN shares currently have a short interest ratio of 4.0. Learn More on Sonnet BioTherapeutics's short interest ratio. What is a good short interest percentage for Sonnet BioTherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 14.40% of Sonnet BioTherapeutics' floating shares are currently sold short. Is Sonnet BioTherapeutics' short interest increasing or decreasing? Sonnet BioTherapeutics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 400,200 shares, a drop of 5.7% from the previous total of 424,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Sonnet BioTherapeutics' float size? Sonnet BioTherapeutics currently has issued a total of 3,069,000 shares. Some of Sonnet BioTherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Sonnet BioTherapeutics currently has a public float of 2,780,000 shares. How does Sonnet BioTherapeutics' short interest compare to its competitors? 14.40% of Sonnet BioTherapeutics' shares are currently sold short. Here is how the short interest of companies compare to Sonnet BioTherapeutics: Genprex, Inc. (2.46%), Protagenic Therapeutics, Inc. (0.26%), Hoth Therapeutics, Inc. (2.73%), Lipella Pharmaceuticals Inc. (1.05%), Adial Pharmaceuticals, Inc. (4.42%), Kineta, Inc. (1.96%), Synaptogenix, Inc. (2.88%), Lixte Biotechnology Holdings, Inc. (1.31%), Enveric Biosciences, Inc. (1.07%), First Wave BioPharma, Inc. (2.39%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Sonnet BioTherapeutics stock? Short selling SONN is an investing strategy that aims to generate trading profit from Sonnet BioTherapeutics as its price is falling. SONN shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Sonnet BioTherapeutics? A short squeeze for Sonnet BioTherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SONN, which in turn drives the price of the stock up even further. How often is Sonnet BioTherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SONN, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Genprex Short Squeeze Protagenic Therapeutics Short Squeeze Hoth Therapeutics Short Squeeze Lipella Pharmaceuticals Short Squeeze Adial Pharmaceuticals Short Squeeze Kineta Short Squeeze Synaptogenix Short Squeeze Lixte Biotechnology Short Squeeze Enveric Biosciences Short Squeeze First Wave BioPharma Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SONN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressHow Biden has already won 2024Porter & Company